{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:23:09Z","timestamp":1786980189762,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,9]],"date-time":"2015-01-09T00:00:00Z","timestamp":1420761600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Microbiol Immunol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s00430-014-0376-8","type":"journal-article","created":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T05:34:05Z","timestamp":1420695245000},"page":"79-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Therapeutic vaccines in HBV: lessons from HCV"],"prefix":"10.1007","volume":"204","author":[{"given":"Eleanor","family":"Barnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,9]]},"reference":[{"key":"376_CR1","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"359","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359:2442\u20132455","journal-title":"N Engl J Med"},{"key":"376_CR2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","volume":"354","author":"CL Lai","year":"2006","unstructured":"Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354:1011\u20131020","journal-title":"N Engl J Med"},{"key":"376_CR3","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001\u20131010","journal-title":"N Engl J Med"},{"key":"376_CR4","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","volume":"146","author":"HL Chan","year":"2014","unstructured":"Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, Gaggar A, Subramanian GM, McHutchison JG, Lee S, Gane EJ (2014) Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 146:1240\u20131248","journal-title":"Gastroenterology"},{"key":"376_CR5","doi-asserted-by":"crossref","first-page":"e98476","DOI":"10.1371\/journal.pone.0098476","volume":"9","author":"MR Li","year":"2014","unstructured":"Li MR, Xi HL, Wang QH, Hou FQ, Huo N, Zhang XX, Li F, Xu XY (2014) Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B. PLoS One 9:e98476","journal-title":"PLoS One"},{"key":"376_CR6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/QCO.0b013e32834cfb2d","volume":"24","author":"J Frater","year":"2011","unstructured":"Frater J (2011) New approaches in HIV eradication research. Curr Opin Infect Dis 24:593\u2013598","journal-title":"Curr Opin Infect Dis"},{"key":"376_CR7","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1084\/jem.181.3.1047","volume":"181","author":"B Rehermann","year":"1995","unstructured":"Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, Moss B, Sette A, Chisari FV (1995) The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181:1047\u20131058","journal-title":"J Exp Med"},{"key":"376_CR8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","volume":"77","author":"R Thimme","year":"2003","unstructured":"Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV (2003) CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77:68\u201376","journal-title":"J Virol"},{"key":"376_CR9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1023366013858","volume":"23","author":"N Shimada","year":"2003","unstructured":"Shimada N, Yamamoto K, Kuroda MJ, Terada R, Hakoda T, Shimomura H, Hata H, Nakayama E, Shiratori Y (2003) HBcAg-specific CD8 T cells play an important role in virus suppression, and acute flare-up is associated with the expansion of activated memory T cells. J Clin Immunol 23:223\u2013232","journal-title":"J Clin Immunol"},{"key":"376_CR10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1046\/j.1440-1746.2003.02976.x","volume":"18","author":"YF Liaw","year":"2003","unstructured":"Liaw YF (2003) Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 18:246\u2013252","journal-title":"J Gastroenterol Hepatol"},{"key":"376_CR11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12072-009-9140-3","volume":"3","author":"YF Liaw","year":"2009","unstructured":"Liaw YF (2009) HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 3:425\u2013433","journal-title":"Hepatol Int"},{"key":"376_CR12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/j.gastro.2004.06.015","volume":"127","author":"GM Lauer","year":"2004","unstructured":"Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Robbins GK, Casson DR, Reiser M, Dusheiko G, Allen TM, Chung RT, Walker BD, Klenerman P (2004) High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127:924\u2013936","journal-title":"Gastroenterology"},{"key":"376_CR13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ni1241","volume":"6","author":"P Klenerman","year":"2005","unstructured":"Klenerman P, Hill A (2005) T cells and viral persistence: lessons from diverse infections. Nat Immunol 6:873\u2013879","journal-title":"Nat Immunol"},{"key":"376_CR14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1034\/j.1600-0528.2002.017408.x","volume":"174","author":"PA Knolle","year":"2000","unstructured":"Knolle PA, Gerken G (2000) Local control of the immune response in the liver. Immunol Rev 174:21\u201334","journal-title":"Immunol Rev"},{"key":"376_CR15","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/hep.21844","volume":"46","author":"JJ Chang","year":"2007","unstructured":"Chang JJ, Thompson AJ, Visvanathan K, Kent SJ, Cameron PU, Wightman F, Desmond P, Locarnini SA, Lewin SR (2007) The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology 46:1332\u20131340","journal-title":"Hepatology"},{"issue":"78\u201387","key":"376_CR16","first-page":"e73","volume":"143","author":"E Sandalova","year":"2012","unstructured":"Sandalova E, Laccabue D, Boni C, Watanabe T, Tan A, Zong HZ, Ferrari C, Bertoletti A (2012) Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells. Gastroenterology 143(78\u201387):e73","journal-title":"Gastroenterology"},{"key":"376_CR17","doi-asserted-by":"crossref","first-page":"8960","DOI":"10.1128\/JVI.79.14.8960-8968.2005","volume":"79","author":"EJ Wherry","year":"2005","unstructured":"Wherry EJ, Blattman JN, Ahmed R (2005) Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol 79:8960\u20138968","journal-title":"J Virol"},{"key":"376_CR18","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1365-2036.2012.05098.x","volume":"35","author":"GL Wong","year":"2012","unstructured":"Wong GL, Wong VW, Chan HY, Tse PC, Wong J, Chim AM, Yiu KK, Chu SH, Chan HL (2012) Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3\u00a0years. Aliment Pharmacol Ther 35:1326\u20131335","journal-title":"Aliment Pharmacol Ther"},{"key":"376_CR19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0168-8278(03)00292-7","volume":"39","author":"C Boni","year":"2003","unstructured":"Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, Pilli M, Urbani S, Cavalli A, Cerioni S, Panebianco R, Jenkins J, Ferrari C (2003) Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 39:595\u2013605","journal-title":"J Hepatol"},{"key":"376_CR20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","volume":"12","author":"J Weber","year":"2007","unstructured":"Weber J (2007) Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12:864\u2013872","journal-title":"Oncologist"},{"key":"376_CR21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd4066","volume":"12","author":"A Mullard","year":"2013","unstructured":"Mullard A (2013) New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 12:489\u2013492","journal-title":"Nat Rev Drug Discov"},{"key":"376_CR22","doi-asserted-by":"crossref","first-page":"15001","DOI":"10.1073\/pnas.1312772110","volume":"110","author":"MJ Fuller","year":"2013","unstructured":"Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, Sharpe AH, Dustin LB, Rice CM, Grakoui A, Ahmed R, Walker CM (2013) Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci USA 110:15001\u201315006","journal-title":"Proc Natl Acad Sci USA"},{"key":"376_CR23","doi-asserted-by":"crossref","first-page":"e63818","DOI":"10.1371\/journal.pone.0063818","volume":"8","author":"D Gardiner","year":"2013","unstructured":"Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, Chang KM, Sulkowski M, Marro SO, Anderson J, He B, Kansra V, McPhee F, Wind-Rotolo M, Grasela D, Selby M, Korman AJ, Lowy I (2013) A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 8:e63818","journal-title":"PLoS One"},{"key":"376_CR24","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454","journal-title":"N Engl J Med"},{"key":"376_CR25","doi-asserted-by":"crossref","first-page":"e1003856","DOI":"10.1371\/journal.ppat.1003856","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, Moller I, Seiz P, Glebe D, Wang B, Yang D, Lu M, Roggendorf M (2014) Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 10:e1003856","journal-title":"PLoS Pathog"},{"key":"376_CR26","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00004836-200310000-00012","volume":"37","author":"K Yalcin","year":"2003","unstructured":"Yalcin K, Danis R, Degertekin H, Alp MN, Tekes S, Budak T (2003) The lack of effect of therapeutic vaccination with a pre-S2\/S HBV vaccine in the immune tolerant phase of chronic HBV infection. J Clin Gastroenterol 37:330\u2013335","journal-title":"J Clin Gastroenterol"},{"key":"376_CR27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s15010-003-3187-1","volume":"31","author":"K Yalcin","year":"2003","unstructured":"Yalcin K, Acar M, Degertekin H (2003) Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection 31:221\u2013225","journal-title":"Infection"},{"key":"376_CR28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0168-8278(01)00028-9","volume":"34","author":"S Pol","year":"2001","unstructured":"Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, Denis J, Brecho C (2001) Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 34:917\u2013921","journal-title":"J Hepatol"},{"key":"376_CR29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1128\/JVI.01505-07","volume":"82","author":"E Depla","year":"2008","unstructured":"Depla E, Van der Aa A, Livingston BD, Crimi C, Allosery K, De Brabandere V, Krakover J, Murthy S, Huang M, Power S, Babe L, Dahlberg C, McKinney D, Sette A, Southwood S, Philip R, Newman MJ, Meheus L (2008) Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J Virol 82:435\u2013450","journal-title":"J Virol"},{"key":"376_CR30","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1016\/j.vaccine.2005.08.013","volume":"24","author":"M Mancini-Bourgine","year":"2006","unstructured":"Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, Michel ML (2006) Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 24:4482\u20134489","journal-title":"Vaccine"},{"key":"376_CR31","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/hep.20408","volume":"40","author":"M Mancini-Bourgine","year":"2004","unstructured":"Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML (2004) Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40:874\u2013882","journal-title":"Hepatology"},{"key":"376_CR32","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/sj.gt.3302751","volume":"13","author":"SH Yang","year":"2006","unstructured":"Yang SH, Lee CG, Park SH, Im SJ, Kim YM, Son JM, Wang JS, Yoon SK, Song MK, Ambrozaitis A, Kharchenko N, Yun YD, Kim CM, Kim CY, Lee SH, Kim BM, Kim WB, Sung YC (2006) Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 13:1110\u20131117","journal-title":"Gene Ther"},{"key":"376_CR33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2893.2012.01589.x","volume":"19","author":"FQ Yang","year":"2012","unstructured":"Yang FQ, Yu YY, Wang GQ, Chen J, Li JH, Li YQ, Rao GR, Mo GY, Luo XR, Chen GM (2012) A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat 19:581\u2013593","journal-title":"J Viral Hepat"},{"key":"376_CR34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/jhep.2001.21594","volume":"33","author":"P Pancholi","year":"2001","unstructured":"Pancholi P, Lee DH, Liu Q, Tackney C, Taylor P, Perkus M, Andrus L, Brotman B, Prince AM (2001) DNA prime\/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 33:448\u2013454","journal-title":"Hepatology"},{"key":"376_CR35","doi-asserted-by":"crossref","first-page":"e14626","DOI":"10.1371\/journal.pone.0014626","volume":"6","author":"JS Cavenaugh","year":"2011","unstructured":"Cavenaugh JS, Awi D, Mendy M, Hill AV, Whittle H, McConkey SJ (2011) Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS One 6:e14626","journal-title":"PLoS One"},{"key":"376_CR36","doi-asserted-by":"crossref","first-page":"e1003391","DOI":"10.1371\/journal.ppat.1003391","volume":"9","author":"AD Kosinska","year":"2013","unstructured":"Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, Wildner O, Dittmer U, Lu M, Roggendorf M (2013) Combination of DNA prime\u2013adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog 9:e1003391","journal-title":"PLoS Pathog"},{"key":"376_CR37","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/hep.1840180405","volume":"18","author":"J Martin","year":"1993","unstructured":"Martin J, Bosch O, Moraleda G, Bartolome J, Quiroga JA, Carreno V (1993) Pilot study of recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of chronic hepatitis B. Hepatology 18:775\u2013780","journal-title":"Hepatology"},{"key":"376_CR38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1046\/j.1440-1746.2002.02794.x","volume":"17","author":"RC Guptan","year":"2002","unstructured":"Guptan RC, Thakur V, Kazim SN, Sarin SK (2002) Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients. J Gastroenterol Hepatol 17:765\u2013771","journal-title":"J Gastroenterol Hepatol"},{"key":"376_CR39","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","volume":"59","author":"DZ Xu","year":"2013","unstructured":"Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH, Zhen Z, Wang HF, Gong HY, Xu C, Jiang N, Pan C, Gong ZJ, Zhang JM, Shang J, Xu J, Xie Q, Wu TF, Huang WX, Li YG, Yuan ZH, Wang B, Zhao K, Wen YM (2013) Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 59:450\u2013456","journal-title":"J Hepatol"},{"key":"376_CR40","doi-asserted-by":"crossref","first-page":"e2565","DOI":"10.1371\/journal.pone.0002565","volume":"3","author":"DZ Xu","year":"2008","unstructured":"Xu DZ, Zhao K, Guo LM, Li LJ, Xie Q, Ren H, Zhang JM, Xu M, Wang HF, Huang WX, Bai XF, Niu JQ, Liu P, Chen XY, Shen XL, Yuan ZH, Wang XY, Wen YM (2008) A randomized controlled phase IIb trial of antigen\u2013antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One 3:e2565","journal-title":"PLoS One"},{"key":"376_CR41","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.4049\/jimmunol.1103139","volume":"189","author":"A Das","year":"2012","unstructured":"Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, Chen A, Blair P, Dusheiko G, Gill U, Kennedy PT, Brunetto M, Lampertico P, Mauri C, Maini MK (2012) IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol 189:3925\u20133935","journal-title":"J Immunol"},{"key":"376_CR42","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1053\/j.gastro.2009.06.054","volume":"137","author":"C Dunn","year":"2009","unstructured":"Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar RM, Brown D, Gilson RJ, Tedder RJ, Dusheiko GM, Jacobs M, Klenerman P, Maini MK (2009) Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137:1289\u20131300","journal-title":"Gastroenterology"},{"key":"376_CR43","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.4049\/jimmunol.180.9.5771","volume":"180","author":"KN Couper","year":"2008","unstructured":"Couper KN, Blount DG, Riley EM (2008) IL-10: the master regulator of immunity to infection. J Immunol 180:5771\u20135777","journal-title":"J Immunol"},{"key":"376_CR44","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1084\/jem.20071948","volume":"205","author":"DG Brooks","year":"2008","unstructured":"Brooks DG, Lee AM, Elsaesser H, McGavern DB, Oldstone MB (2008) IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J Exp Med 205:533\u2013541","journal-title":"J Exp Med"},{"key":"376_CR45","doi-asserted-by":"crossref","first-page":"e1003208","DOI":"10.1371\/journal.ppat.1003208","volume":"9","author":"A Schurich","year":"2013","unstructured":"Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, Nastouli E, Tanwar S, Rosenberg W, Maini MK (2013) The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog 9:e1003208","journal-title":"PLoS Pathog"},{"key":"376_CR46","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1158\/1078-0432.CCR-07-0776","volume":"13","author":"M Vecchio Del","year":"2007","unstructured":"Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A (2007) Interleukin-12: biological properties and clinical application. Clin Cancer Res 13:4677\u20134685","journal-title":"Clin Cancer Res"},{"key":"376_CR47","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","volume":"372","author":"SP Buchbinder","year":"2008","unstructured":"Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881\u20131893","journal-title":"Lancet"},{"key":"376_CR48","doi-asserted-by":"crossref","first-page":"115ra112","DOI":"10.1126\/scitranslmed.3002925","volume":"4","author":"S Colloca","year":"2012","unstructured":"Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O\u2019Hara GA, Ewer KJ, Anagnostou N, Bliss C, Hill AV, Traboni C, Klenerman P, Cortese R, Nicosia A (2012) Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4:115ra112","journal-title":"Sci Transl Med"},{"key":"376_CR49","doi-asserted-by":"crossref","first-page":"115ra111","DOI":"10.1126\/scitranslmed.3003155","volume":"4","author":"E Barnes","year":"2012","unstructured":"Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O\u2019Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P (2012) Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4:115ra111","journal-title":"Sci Transl Med"},{"key":"376_CR50","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1128\/JVI.78.11.5707-5719.2004","volume":"78","author":"GJ Webster","year":"2004","unstructured":"Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, Williams R, Dusheiko G, Bertoletti A (2004) Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 78:5707\u20135719","journal-title":"J Virol"},{"key":"376_CR51","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/ng.348","volume":"41","author":"Y Kamatani","year":"2009","unstructured":"Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, Kubo M, Tsunoda T, Kamatani N, Kumada H, Puseenam A, Sura T, Daigo Y, Chayama K, Chantratita W, Nakamura Y, Matsuda K (2009) A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 41:591\u2013595","journal-title":"Nat Genet"},{"key":"376_CR52","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0168-8278(11)60067-6","volume":"54","author":"C Kelly","year":"2011","unstructured":"Kelly C, Folgori A, Capone S, Stafford E (2011) A therapeutic vaccine for HCV based on novel, rare, adenoviral vectors. J Hepatol 54:S29","journal-title":"J Hepatol"},{"key":"376_CR53","doi-asserted-by":"crossref","unstructured":"Kelly C, Folgori A, Capone S (2012) In vivo antigenic targets of T cells induced by adenoviral vectored vaccines in patients with chronic HCV infection. J Hepatol S468","DOI":"10.1016\/S0168-8278(12)61195-7"},{"key":"376_CR54","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1086\/597072","volume":"199","author":"E Barnes","year":"2009","unstructured":"Barnes E, Gelderblom HC, Humphreys I, Semmo N, Reesink HW, Beld MG, van Lier RA, Klenerman P (2009) Cellular immune responses during high-dose interferon-\u03b1 induction therapy for hepatitis C virus infection. J Infect Dis 199:819\u2013828","journal-title":"J Infect Dis"},{"key":"376_CR55","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1053\/j.gastro.2009.07.050","volume":"137","author":"Y Liang","year":"2009","unstructured":"Liang Y, Shilagard T, Xiao SY, Snyder N, Lau D, Cicalese L, Weiss H, Vargas G, Lemon SM (2009) Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 137:1448\u20131458","journal-title":"Gastroenterology"},{"issue":"890\u2013899","key":"376_CR56","first-page":"e891","volume":"141","author":"F Habersetzer","year":"2011","unstructured":"Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, Feray C, Baumert TF, Bronowicki JP, Doffoel M, Trepo C, Agathon D, Toh ML, Baudin M, Bonnefoy JY, Limacher JM, Inchauspe G (2011) A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 141(890\u2013899):e891\u2013e894","journal-title":"Gastroenterology"},{"issue":"119\u2013131","key":"376_CR57","first-page":"e113","volume":"147","author":"AM Bisceglie Di","year":"2014","unstructured":"Di Bisceglie AM, Janczweska-Kazek E, Habersetzer F, Mazur W, Stanciu C, Carreno V, Tanasescu C, Flisiak R, Romero-Gomez M, Fich A, Bataille V, Toh ML, Hennequi M, Zerr P, Honnet G, Inchauspe G, Agathon D, Limacher JM, Wedemeyer H (2014) Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a phase 2 study of patients with chronic HCV infection. Gastroenterology 147(119\u2013131):e113","journal-title":"Gastroenterology"},{"key":"376_CR58","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","volume":"343","author":"J Lucifora","year":"2014","unstructured":"Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Huser N, Durantel D, Liang TJ, Munk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U (2014) Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343:1221\u20131228","journal-title":"Science"},{"key":"376_CR59","doi-asserted-by":"crossref","unstructured":"Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, Fosdick A, Frey CR, Zheng J, Wolfgang G, Halcomb RL, Tumas DB (2013) GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144 1508\u20131517, 1517 e1501\u20131510","DOI":"10.1053\/j.gastro.2013.02.003"},{"key":"376_CR60","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1742-4690-10-134","volume":"10","author":"DF Purcell","year":"2013","unstructured":"Purcell DF, Elliott JH, Ross AL, Frater J (2013) Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium. Retrovirology 10:134","journal-title":"Retrovirology"},{"key":"376_CR61","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1128\/JVI.03533-12","volume":"87","author":"G Zhong","year":"2013","unstructured":"Zhong G, Yan H, Wang H, He W, Jing Z, Qi Y, Fu L, Gao Z, Huang Y, Xu G, Feng X, Sui J, Li W (2013) Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes. J Virol 87:7176\u20137184","journal-title":"J Virol"},{"key":"376_CR62","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","volume":"1","author":"H Yan","year":"2012","unstructured":"Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1:e00049","journal-title":"Elife"}],"container-title":["Medical Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00430-014-0376-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-014-0376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-014-0376-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T15:51:45Z","timestamp":1598629905000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00430-014-0376-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,9]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["376"],"URL":"https:\/\/doi.org\/10.1007\/s00430-014-0376-8","relation":{},"ISSN":["0300-8584","1432-1831"],"issn-type":[{"value":"0300-8584","type":"print"},{"value":"1432-1831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,9]]}}}